U.S. Meibomian Gland Dysfunction Market Size, Trends, Shares, Insights,2027

U.S. MEIBOMIAN GLAND DYSFUNCTION MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027

REPORT DESCRIPTION U.S. Meibomian Gland Dysfunction Market - Overview U.S. Meibomian Gland Dysfunction Market, By Drug Type (Cyclosporine, Omega-3 supplements, Antibacterial Eye Drops, Steroids, AZR MD 001, TP 03, NOV03 (Novatears), and HY02–Minocycline), By Route of Administration (Oral and Topical), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), is estimated to be valued at US$ 1,976.6 million in 2020 and is expected to exhibit a CAGR of 15.4% during the forecast period (2020-2030), as highlighted in a new report published by Coherent Market Insights. Key players operating in the market are focusing on launching innovative products for the treatment of meibomian gland dysfunction syndrome, which is expected to drive the market growth during the forecast period. For instance, in November 2017, TearScience, a part of Johnson and Johnson Vision Care Inc., launched LipiScan and LipiFlow technologies at the American Academy of Ophthalmology’s 2017 meeting. The technologies are used to treat meibomian gland dysfunction (MGD), a cause of dry eye disease. In July 2018, Allergan Plc., now a subsidiary of Abbvie Inc., launched REFRESH REPAIR Lubricant Eye Drops, an over-the-counter (OTC) artificial tear formulation. Browse Research Reports: https://www.coherentmarketinsights.com/market-insight/usmeibomian-gland-dysfunction-market-4186 © Coherent market Insights. All Rights Reserved

REPORT DESCRIPTION U.S. Meibomian Gland Dysfunction Market – Impact of Coronavirus (COVID-19) Pandemic Key players operating in the market have a robust product pipeline for treatment of dry eye associated meibomian gland dysfunction. The players are focusing on changes in clinical enrollment studies associated with the COVID-19, which will help to complete the clinical trials on time. For instance, in March 2020, RegeneRx, a clinical-stage drug development company announced that GtreeBNT, its Korean partner in the U.S. for development of RGN-259 for the treatment of dry eye disease, issued an update on the status of the company’s U.S. phase 3 dry eye clinical trial. The GtreeBNT team met with the contract research organization (CRO) managing the ARISE-3 trial, to discuss any changes or projected changes in enrollment associated with the COVID-19 virus. They are also developing contingency plans based on future developments or restrictions enacted by the U.S. and/or World Health Organization. Thus, there have been no major disruptions or delays in ARISE-3 trial and, if modifications are needed in the clinical plan due to COVID-19, GtreeBNT will notify its stockholders immediately through the GtreeBNT web-site. For instance, in April 2020, the National Centers for Biotechnological Information published results of a study which showed that since December 2019, COVID-19 has become a global pandemic caused by the highly transmissible severe acute respiratory syndrome coronavirus. Request a Sample copy of this reports : https://www.coherentmarketinsights.com/insight/request-sample/4186 © Coherent market Insights. All Rights Reserved

REPORT DESCRIPTION Key Takeaways of the U.S. Meibomian Gland Dysfunction Market: The U.S. meibomian gland dysfunction market is expected to expand at a CAGR of 15.4% during the forecast period owing to a robust product pipeline for the treatment of meibomian gland dysfunction. For instance, in December 2019, Aldeyra Therapeutics, Inc., a biotechnology company, announced positive results from its Phase 2b clinical trial of topical ocular reproxalap in patients with dry eye disease associated meibomian gland dysfunction syndrome. Reproxalap is a first-in-class therapy with a novel mechanism of action, with no significant side effects and a rapid onset of action. Among drug type, the Cyclosporine segment holds a dominant position in the U.S. meibomian gland dysfunction market in 2020, owing launch of novel products. For instance, in August 2018, Sun Pharma received approval for Cequa (cyclosporine ophthalmic solution) 0.09% from the U.S. FDA. The drug is indicated for increasing tear production in patients with dry eye disease. Cequa is the only approved cyclosporine product that incorporates nanomicellar technology and allows better penetration of active molecule into ocular tissues.

Among route of administration, the topical segment is expected to hold a dominant position in the U.S. meibomian gland dysfunction market in 2020 owing to easy availability of over-thecounter eye drops, eye ointments and artificial tear solutions for treatment of dry eye associated meibomian gland dysfunction.

ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele.

SERVICES INDUSTRY ANALYSIS

CUSTOMIZED RESEARCH

SYNDICATED RESEARCH

MARKET INTELLIGENCE SERVICES

CONSULT STUDIES

COUNTRY SPECIFIC STUDIES

ABOUT CMI SECTOR COVERAGE

BIOTECHNOLOGY

CLINICAL DIAGNOSTIC

HEALTHCARE IT

MEDICAL DEVICES

MEDICAL IMAGING

PHARMACEUTICAL

OUR CLIENTS

 Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators

 Private and Government organization

 Distributors, Retailors and Value Added Resellers

 Outsourcing Companies

 Healthcare IT Solutions Developers

 Universities and Business Schools.

KEY STATS

RESEARCH SOLUTIONS

100+

FEASIBILITY STUDIES

Insights Published Per Year

GLOBAL REPORTS

150+

Consulting Projects Till Date

COUNTRY ANALYSIS CONSULT PROJECTS

125+

Clients Worldwide Per Year

110+

SURVEY RESEARCH

EXCEL FORECAST DATABASE

CUSTOMIZED SOLUTIONS

COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS

Analysts and Contract Consultants

Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702

Turn static files into dynamic content formats.

Create a flipbook